

Beludavimab

Cat. No.:	HY-P99467
CAS No.:	2423016-74-2
Target:	SARS-CoV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC ₅₀ value of 14.9 ng/mL and a K _d of 0.21 nM ^[1] .
In Vitro	Beludavimab (VIR 7832) targets an epitope containing a glycan (at position N343) that is highly conserved within the Sarbecovirus subgenus in a region of the S receptor binding domain (RBD) that does not compete with angiotensin converting enzyme 2 (ACE2) binding. Beludavimab possesses an Fc “LS” mutation that confers extended half-life by binding to the neonatal Fc receptor ^[1] . Beludavimab induces NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) in cells from donors expressing the low-affinity F/F158 allele of FcγIIIa more efficiently. Beludavimab neutralizes wild-type and variant pseudotyped viruses and authentic virus in vitro ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Andrea L. Cathcart, et al. The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2. bioRxiv. April 01, 2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA